Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: Association with serum alpha-fetoprotein and hepatocellular carcinoma

Liver International

Volumn 32, Issue 9, 2012, Pages 1382-1390

  Sato, Shunsuke ^a   Genda, Takuya ^a   Hirano, Katsuharu ^a   Tsuzura, Hironori ^a   Narita, Yutaka ^a   Kanemitsu, Yoshio ^a   Kikuchi, Tetsu ^a   Iijima, Katsuyori ^a   Wada, Ryo ^a   Ichida, Takafumi ^a  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

Author keywords

AKR1B10; Alpha fetoprotein; Carcinogenesis; Chronic hepatitis C; Liver; Microarray; Risk factor

Indexed keywords

ALDO KETO REDUCTASE FAMILY 1 MEMBER B10; ALPHA FETOPROTEIN; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ALDEHYDE REDUCTASE; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84865746463     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02827.x     Document Type: Article

References (36)

1. EI-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
3. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S17-26.
4. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
5. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large prognostic cohort study. Hepatology 1998; 28: 1687-95.
6. Sun CA, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12, 008 men in Taiwan. Am J Epidemiol 2003; 157: 674-82.
7. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43: 434-41.
8. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
9. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
10. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
11. Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2011; 46: 92-100.
12. Kumada T, Toyoda H, Kiriyama S, et al. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol 2011; 46: 536-44.
13. Bedossa P, Poynard T. For the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
14. Heringlake S, Hofdmann M, Fiebeler A, et al. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumors. J Hepatol 2010; 52: 220-7.
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
16. Scuric Z, Stain SC, Anderson WF, Hwang JJ. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 1998; 27: 943-50.
17. Cao D, Fan ST, Chung SSM. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 1998; 273: 11429-35.
18. Liu Z, Zhong L, Krishack PA, et al. Structure and promoter characterization of aldo-keto reductase family1 B10 gene. Gene 2009; 437: 39-44.
19. Nishinaka T, Miura T, Okumura M, et al. Regulation of aldo-keto reductase AKR1B10 gene expression: involvement of transcription factor Nrf2. Chem Biol Interact 2011; 191: 185-91.
20. Crosas B, Hyndman DJ, Gallego O, et al. Human aldose reductase and human intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J 2003; 373: 973-9.
21. Gallego O, Ruiz FX, Ardèvol A, et al. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA 2007; 104: 20764-9.
22. Penning TM. AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res 2005; 11: 1687-90.
23. Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble A vitamin. J Exp Med 1925; 42: 753-78.
24. Lancilloti F, Darwiche N, Celli G, De Luca LM. Retinoid status and the control of keratin expression and adhesion during the histogenesis of squamous metaplasia of tracheal epithelium. Cancer Res 1992; 52: 6144-52.
25. Darwiche N, Celli G, Sly L, Lancilloti F, De Luca LM. Retinoid status controls the appearance of reserve cells and keratin expression in mouse cervical epithelium. Cancer Res 1993; 53: 2287-99.
26. Schroder EW, Rapaport E, Kabcenell AK, Black PH. Growth inhibitory and stimulatory effects of retinoic acid on murine 3T3 cells. Proc Natl Acad Sci USA 1982; 79: 1549-52.
27. Takatsuka J, Takahashi N, De Luca LM. Retinoic acid metabolism and inhibition of cell proliferation: an unexpected liaison. Cancer Res 1996; 56: 675-8.
28. Tannenbaum T, Lowry D, Darwiche N, et al. Topical retinoic acid reduces skin papilloma formation but resistant papillomas are at high risk for malignant conversion. Cancer Res 1998; 58: 1435-43.
29. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1999; 340: 1046-7.
30. Deisenroth C, Thorner AR, Enomoto T, et al. Mitochondrial HEP27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Mol Cell Biochem 2010; 30: 3981-93.
31. Satow R, Shitashige M, Kanai Y, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res 2010; 16: 2518-28.
32. Schmitz KJ, Sotiropoulos GC, Baba HA, et al. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. Liver Int 2011; 31: 810-6.
33. Li CP, Goto A, Watanabe A, et al. AKR1B10 in usual interstitial pneumonia: expression in squamous metaplasia in association with smoking and lung cancer. Pathol Res Pract 2008; 204: 295-304.
34. Breton J, Gage MC, Hay AW, et al. Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma. J Proteome Res 2008; 7: 1953-62.
35. Yan R, Zu X, Ma J, et al. Aldo-keto reductase family 1B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int J Cancer 2007; 121: 2301-6.
36. Teramoto R, Minagawa H, Honda M, et al. Protein expression profile characteristics to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta 2008; 1784: 764-72.